Desmopressin — Discount Pricing

Other medications in Hormones

• Estradiol
• Fludrocortisone
• Letrozole
• Medroxyprogesterone
• Norethindrone
• Octreotide
• Progesterone
• Tamoxifen

About Desmopressin

Desmopressin is a vital medication used to manage conditions such as nocturnal enuresis (bedwetting), nocturia (frequent nighttime urination), and central diabetes insipidus. It works by helping your body regulate water balance, reducing urine production. At TheDrugClub, we understand the importance of affordable healthcare and strive to make essential prescriptions like desmopressin more accessible for our members.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Desmopressin is approved for (FDA label)

Desmopressin acetate injection is a vasopressin analog used for: Central Diabetes Insipidus - as antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. ( 1.1 ) Hemophilia A- for patients with factor VIII coagulant activity levels greater than 5% to maintain hemostasis during surgical procedures and postoperatively or reduce bleeding with episodes of spontaneous or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. ( 1.2 ) von Willebrand’s disease (Type I) - for patients with mild to moderate disease with factor VIII levels greater than 5% to maintain hemostasis during surgical procedures or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. ( 1.3 ) Limitations of Use Desmopressin acetate is ineffective and not indicated for the treatment of nephrogenic diabetes insipidus. ( 1.3 ) von Willebrand’s disease (severe Type I) - not indicated for the treatment of patients with severe Type I von Willebrand’s disease and when there is evidence of an abnormal molecular form of factor VIII antigen. ( 1.3 ) 1.1 Central Diabetes Insipidus Desmopressin acetate injection is indicated as antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region.

Source: Read the full FDA label on DailyMed. Label effective date: August 27, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Desmopressin (FDA label)

WARNING: HYPONATREMIA Desmopressin acetate can cause hyponatremia. Severe hyponatremia can be life-threatening, leading to seizures, coma, respiratory arrest, or death [see Warnings and Precautions ( 5.1 )] . Desmopressin acetate is contraindicated in patients at increased risk of severe hyponatremia, such as patients with excessive fluid intake, illnesses that can cause fluid or electrolyte imbalances, and in those using loop diuretics or systemic or inhaled glucocorticoids [see Contraindications ( 4 ) and Warnings and Precautions ( 5.1 )]. Ensure the serum sodium concentration is normal before starting or resuming desmopressin acetate. Measure serum sodium within 7 days and approximately 1 month after initiating therapy, and periodically during treatment. More frequently monitor serum sodium in patients 65 years of age and older and in patients at increased risk of hyponatremia [see Dosage and Administration ( 2.1 ) and Warnings and Precautions ( 5.1 )]. If hyponatremia occurs, desmopressin acetate may need to be temporarily or permanently discontinued [see Warnings and Precautions ( 5.1 )]. WARNING: HYPONATREMIA See full prescribing information for complete boxed warning.

Source: FDA prescribing information (DailyMed). Set ID: 52680415-52a0-61c2-e063-6294a90ae27e. SPL document ID: 5a144051-0656-4da5-e063-6294a90a18cf. Label effective date: August 27, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Desmopressin (FDA label)

Injection: desmopressin acetate injection, USP is a sterile, aqueous, colorless solution available as: 40 mcg/10 mL (4 mcg/mL) in multiple-dose vial. Injection: 40 mcg per 10 mL (4 mcg/mL) in a multiple-dose vial. ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 52680415-52a0-61c2-e063-6294a90ae27e. SPL document ID: 5a144051-0656-4da5-e063-6294a90a18cf. Label effective date: August 27, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Desmopressin (FDA label)

The following clinically significant adverse reactions are described elsewhere in the labeling: Hyponatremia [see Contraindications, Warnings and Precautions ( 5.1 )] Hypotension and Hypertension [see Warnings and Precautions ( 5.2 )] Increased risk of thrombosis in patients with von Willebrand’s Disease Type IIB [see Warnings and Precautions ( 5.3 )] Hypersensitivity reactions [see Warnings and Precautions ( 5.4 )] Fluid retention [see Warnings and Precautions ( 5.5 )] The following adverse reactions have been identified during post-approval use of desmopressin acetate injection. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Source: FDA prescribing information (DailyMed). Set ID: 52680415-52a0-61c2-e063-6294a90ae27e. SPL document ID: 5a144051-0656-4da5-e063-6294a90a18cf. Label effective date: August 27, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Desmopressin (FDA label)

Desmopressin acetate injection is contraindicated in patients with known hypersensitivity to desmopressin acetate or to any of the components of desmopressin acetate injection [see Warnings and Precautions ( 5.4 ), Adverse Reactions ( 6 ), Description ( 11 )] . Desmopressin acetate injection is contraindicated in patients with the following conditions due to an increased risk of hyponatremia: Moderate to severe renal impairment defined as a creatinine clearance below 50 mL/min [see Use in Specific Populations ( 8.5 , 8.6 ) and Clinical Pharmacology ( 12.3 )]. Hyponatremia or a history of hyponatremia [see Warnings and Precautions ( 5.1 ), Drug Interactions ( 7.1 ), Use in Specific Populations ( 8.4 , 8.5 )] . Known or suspected syndrome of inappropriate antidiuretic hormone (SIADH) secretion [see Warnings and Precautions ( 5.1 )] . Polydipsia [see Warnings and Precautions ( 5.1 )]. Concomitant use with loop diuretics [see Boxed Warning ]

Source: FDA prescribing information (DailyMed). Set ID: 52680415-52a0-61c2-e063-6294a90ae27e. SPL document ID: 5a144051-0656-4da5-e063-6294a90a18cf. Label effective date: August 27, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.